-
Mashup Score: 1ESC 23: ARAMIS: Anakinra versus Placebo in Acute Myocarditis - 8 month(s) ago
ESC 23 – We are joined onsite by Dr Mathieu Kerneis (Pitie Salpetriere APHP University Hospital, FR) and Dr Gilles Montalescot to discuss the findings from the ARAMIS trial. ARAMIS was the
Source: www.ecrjournal.comCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 4ESC 23: FRAIL-AF: Non-Vitamin K Antagonist Anticoagulation in Frail Elderly Patients With AF - 8 month(s) ago
ESC 2023 — Dr Linda Joosten (Julius Center for Health Sciences and Primary Care, NL) joins us to discuss the findings of the FRAIL-AF trial. FRAIL-AF is a multicentre,
Source: www.aerjournal.comCategories: Latest Headlines, Partners & KOLsTweet-
🫀NEW #ESCCongress #LBCT Interview 💫Dr Linda Joosten joins us to discuss findings from the FRAIL-AF trial. 📽️Watch in full here👉 https://t.co/g8Jdhhvahs 📊Results showed higher bleeding complications in frail elderly patients with AF when switching from VKA treatment to NOACs… https://t.co/TxbuXZYuRQ https://t.co/31KjgMMRfN
-
-
Mashup Score: 10ESC 23: PUSH-AHF: Natriuresis-Guided Therapy in Acute Heart Failure - 8 month(s) ago
ESC 2023 — Dr Jozine Ter Maaten (University Medical Centre Groningen, NL) joins us to outline the findings from the PUSH-AHF Study (NCT04606927). PUSH-AHF (University Medical
Source: www.cfrjournal.comCategories: Latest Headlines, Partners & KOLsTweet-
🫀NEW #ESCCongress #LBCT Interview 💫Dr @jozinetm outlines findings from the PUSH-AHF study. 📽️Watch in full here👉 https://t.co/zfCS6yPId9 📊Results suggested that patients who were treated with natriuresis-guided therapy had significantly greater 24-hour natriuresis without… https://t.co/hC7RcmIm8T https://t.co/1I95BOWVGW
-
-
Mashup Score: 3ESC 23: ReDS-SAFE HF: ReDS-Guided Strategy in Heart Failure - 8 month(s) ago
ESC 23 — Dr Jesus Alvarez-Garcia (Ramon and Cajal University Hospital, ES) considers the use of ReDS technology in patients with acute heart failure (ReDS-SAFE HF) (NCT04305717) in this
Source: www.cfrjournal.comCategories: Latest Headlines, Partners & KOLsTweet-
🫀NEW #ESCCongress #LBCT Interview 💫Dr @j_alvarezgarcia discusses findings from the ReDS-SAFE HF study. 📽️Watch in full here👉 https://t.co/pY7FNBJW4q 📊Results suggest that the ReDS-guided strategy significantly reduced the primary outcome with a hazard ratio of 0.094.… https://t.co/MujQOyyLDf https://t.co/VF0XnrjYZx
-
-
Mashup Score: 3
ESC 2023 — Dr Alan Bulava (Ceske Budejovice Hospital and University of South Bohemia, CZ) joins us in this succinct interview to discuss the findings from the
Source: www.aerjournal.comCategories: Latest Headlines, Partners & KOLsTweet-
🫀NEW #ESCCongress #LBCT Interview 💫Prof Alan Bulava joins us to discuss findings from the SurHyb trial. 📽️Watch in full here👉 https://t.co/2Mt18Qllpz 📊Findings suggest that the incidence of atrial fibrillation and atrial tachycardia was reduced by 62%. The absolute risk… https://t.co/5W09s0OBme https://t.co/7WmKgMqgeh
-
-
Mashup Score: 2ESC 23: HEART-FID: Ferric Carboxymaltose in HF with Iron Deficiency - 8 month(s) ago
ESC 2023 — Dr Robert Mentz (Duke University Medical Center, US) joins us to provide a succinct summary of the findings and key take-home messages from the HEART-FID
Source: www.cfrjournal.comCategories: Latest Headlines, Partners & KOLsTweet-
NEW #ESCCongress #LBCT Interview 💫Dr @robmentz summarises the HEART-FID study results 📽️👉 https://t.co/J9uecqPSrM 📊Results suggest FCM is safe in pts with #HFpEF & iron deficiency, showing a modest improvement in all-cause mortality (1.7% ARR), HF hospitalisations, and 6MWD. https://t.co/zk0kLmrOno
-
-
Mashup Score: 4ESC 23: OCEAN(a)-DOSE: Olpasiran in Patients with Atherosclerotic CVD and Elevated LP(a) - 8 month(s) ago
ESC 23 — Dr Michelle O’Donoghue (Brigham and Women’s Hospital, US) outlines a trial update from OCEAN(a)-Dose (NCT05581303) in this succinct interview. OCEAN(a)-DOSE (Amgen) was
Source: www.ecrjournal.comCategories: Latest Headlines, Partners & KOLsTweet-
🫀NEW #ESCCongress #LBCT Interview 💫 @DrM_Odonoghue outlines a trial update from the olpasiran trials of cardiovascular events and lipoprotein(a) reduction (OCEAN(a)-Dose). 📽️Watch in full here👉 https://t.co/RNKhaGHqdG 📊This late-breaking update revealed that patients… https://t.co/t3QpKuBr4t https://t.co/UaKilS1B8c
-
-
Mashup Score: 0
ESC 23 — Dr Myeong-Ki Hong (Yonsei University College of Medicine, KR) outlines the late-breaking results from the LODESTAR trial (NCT02579499). LODESTAR (Yonsei University) was
Source: www.ecrjournal.comCategories: Latest Headlines, Partners & KOLsTweet-
🫀NEW #ESCCongress #LBCT Interview 💫Prof Myeong-Ki Hong joins us to discuss findings from the LODESTAR trial. 📽️Watch in full here👉 https://t.co/UEUsITCpVy 📊The trial aimed to compare the clinical efficacy and safety of atorvastatin vs rosuvastatin for the secondary… https://t.co/WLC5oshuCH https://t.co/MxFHse1HaD
-
-
Mashup Score: 1
ESC 2023 — Dr Robert Byrne (Mater Private Hospital, Dublin, IE) joins us on-site to discuss the new guidelines from the ESC covering the management of acute coronary
Source: www.ecrjournal.comCategories: Latest Headlines, Partners & KOLsTweet-
🫀NEW #ESCCongress #LBCT Interview 💫Dr @robebyrne discusses the highly anticipated first guidelines from the ESC covering the management of acute coronary syndromes. 📽️Watch in full here👉 https://t.co/tWB9aVfhWO 📊The combined guidelines outlined a common pathway for the… https://t.co/UTG8CQaLSM https://t.co/4glJKQtF4x
-
-
Mashup Score: 0Women are Underrepresented in Cardiovascular Clinical Trials - 11 month(s) ago
May 10, 2023 — A new study has shown that women are underrepresented in late-breaking cardiovascular clinical trials (LBCT) presented at national meetings. The study is published in the peer-reviewed Journal of Women’s Health. LBCT can have an impact on novel drug and device approvals, intervention indications, and patient management, according to Martha Gulati, MD, MS, from Smidt Heart…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet-
@DAICeditor A new study has shown that #women are #underrepresented in #latebreaking #cardiovascular #clinicaltrials (#LBCT) presented at national meetings: https://t.co/80zR1aVTPk
-
🫀NEW #ESCCongress #LBCT Interview 💫Dr @mathieukerneis and Dr Gilles Montalescot discuss findings from the #ARAMIS trial. 📽️👉 https://t.co/zg9bByyrEO 📊Results showed that #anakinra was safe but did not reduce the complications of acute myocarditis. #ESC2023 #CardioTwitter https://t.co/9AGMF59hbX